CD8A and cancer: Finally, we combined MC-TG treatment with two different modalities of cancer immunotherapy and found that our MDSC-depleting strategy enhanced adoptive T cell therapy and led to an enhanced effector phenotype of transferred OT-I CD8+ T cells (Fig. 6).